Advanced Search:
Equity Index

BGBIO.OL - BERGENBIO

kr0.14  -0.0104 (-6.82%)

Updated: 08:24 May 7, 2024 EST

Next Session's AI Forecast

-255.24%

Avg. Accuracy (AI)

kr-0.19

Next Week's AI Forecast

100%

Trend's Accuracy (AI)

kr-1.26

BERGENBIO's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

BERGENBIO - HISTORICAL DATA 6M

  • Last price

    kr0.14

  • Daily change

    kr-0.0104

  • Previous Close

    kr0.1528

  • Last Updated

    08:24 May 7, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
-1.44 -1.06 -1.45 -0.24 -0.19

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
5.09 2.85 4.7 4.63 6.31

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
0% 0% 0% 0%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
% % %

RSI METRIC

RS Hour RSI Hour RS Day RSI Day

BERGENBIO Technical Analysis News

BERGENBIO

Møllendalsbakken 9
Bergen 5009
Norway
47 55 96 11 59
https://www.bergenbio.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 18
Description

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Corporate Governance

BerGenBio ASA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

BERGENBIO'S HOLDERS RANK

List of holders with stock participation in BERGENBIO.

Holder Rank Holder Shares Date Reported % Out Value